| Next 10 |
Ad
RCUS News and Press Arcus Biosciences Inc.
News | Arcus Biosciences Inc. (NYSE:RCUS)
-
– Clinically Meaningful Reduction in Risk of Progression or Death Was Observed in the Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC – – Objective Response Rate (ORR) Improved in Both Domvanalimab-Containing...
-
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Goldman Sachs 44 th Annual ...
-
2023-05-26 10:05:44 ET Gainers: Elevation Oncology ( ELEV ) +58% . Arcus Biosciences ( RCUS ) +26% . Healthcare Triangle ( HCTI ) +17% . PDS Biotechnology ( PDSB ) +16% . NEXGEL ( NXGL ) +12% . Losers: Tilray Brands (...
-
2023-05-26 08:34:32 ET Onfolio Holdings ( ONFO ) +62% Completes Development of Generative AI Search Tool. Elevation Oncology ( ELEV ) +58% . Quhuo Limited ( QH ) +37% Sector Exceeded RMB12 Million in Sales During the Labor Day Holiday, Achieving Impre...
-
2023-05-17 13:29:03 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Even the most experienced investors have only so many hours in the day to perform their due diligence. That’s where analyst ratings can be helpful. Analyst upgrades and downgrades freq...
-
Updated data from ARC-7, the randomized Phase 2 study of domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, will be presented in a special ASCO plenary series rapid abstract update session by Melissa L. Johnson, M.D., Director, Lung Cancer Research, Sarah Cannon Research Institute, and Le...
-
– Gilead to Have Early Option to Exclusively License Drug Candidates Against up to Four Targets for Inflammatory Diseases – – Expanded Research Collaboration May Result in up to $1 Billion in Option Fees and Milestone Payments by Gilead to Arcus – ...
-
2023-05-09 17:31:40 ET Arcus Biosciences press release ( NYSE: RCUS ): Q1 GAAP EPS of -$1.09 beats by $0.10 . Revenue of $25M (+38.8% Y/Y) beats by $2.53M . With $1.0 billion in cash, cash equivalents and marketable securities and funding into 2026, Arcus is we...
- RCUS - Arcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline Update
Four Phase 3 and two Phase 2 trials are now enrolling to evaluate domvanalimab-based combinations in lung and gastrointestinal cancers. The third dose-escalation cohort (100mg) of ARC-20 for AB521, a potential best-in-class HIF-2a inhibitor, is enrolling; the dose-expansion stage of A...
-
2023-03-23 00:58:07 ET Summary Arcus’s pipeline includes several promising candidates, including domvanalimab, an Fc-silent anti-TIGIT antibody, and zimberelimab, an anti-PD-1 antibody. Arcus recently announced positive results from the fourth interim analysis of the random...
Stock Information
Arcus Biosciences Inc. Company Name:
RCUS Stock Symbol:
NYSE Market:
Arcus Biosciences Inc. Website:
Get RCUS Alerts
News, Short Squeeze, Breakout and More Instantly...
Ad
